Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 7/20 | 0.41 |
| ▸ | HTR2C | P28335 | 7/20 | 0.41 |
| ▸ | HTR2B | P41595 | 7/20 | 0.41 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.36 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | CTSG | P08311 | 1/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
| ▸ | CTRC | Q99895 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6213251 | 0.80 | OPRM1 (0.50) | OPRM1ADRB1HTR2AHTR2CHTR2B | |
| SCHEMBL7238311 | 0.80 | OPRM1 (0.50) | OPRM1HTR2AHTR2CHTR2BCHRNB2 | |
| SCHEMBL26326855 | 0.79 | LMNA (0.40) | ADRB1F2ELANECTSGCMA1 | |
| SCHEMBL7239902 | 0.79 | OPRM1 (0.62) | OPRM1ADRB1HTR2AHTR2CHTR2B | |
| SCHEMBL19838619 | 0.79 | OPRM1 (0.62) | OPRM1ADRB1HTR2AHTR2CHTR2B | |
| SCHEMBL26948157 | 0.78 | HTR2A (0.50) | ADRB1HTR2AHTR2CHTR2B | |
| SCHEMBL24681531 | 0.76 | OPRM1 (0.53) | OPRM1ADRB1F2ELANECTSG | |
| SCHEMBL20217205 | 0.76 | PKM (0.38) | ADRB1F2ELANECTSGCMA1 | |
| SCHEMBL21256943 | 0.76 | PIK3CA (0.38) | ADRB1F2ELANECTSGCMA1 | |
| SCHEMBL22919225 | 0.76 | HRH3 (0.49) | OPRM1HTR2AHTR2CHTR2BCHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6531468-B2 | Inhibiting serotonin reuptake in the central nervous system of a mammal | PFIZER INC | 2003-03-11 | — | — | US | claimed |
| US-20020068748-A1 | Diazabicyclooctane derivatives and therapeutic uses thereof | PFIZER INC. | 2002-06-06 | — | — | US | claimed |
| EP-4289835-A1 | CDK INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-6531468-B2 | Inhibiting serotonin reuptake in the central nervous system of a mammal | PFIZER INC | 2003-03-11 | — | — | US | disclosed |
| US-20020068748-A1 | Diazabicyclooctane derivatives and therapeutic uses thereof | PFIZER INC. | 2002-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068748-A1 | Diazabicyclooctane derivatives and therapeutic uses thereof | CNR1, CBR1, CLIC1 | OPRM1 143/4885ADRB1 383/4885HTR2A 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.